NCT07066540
Trial of the Efficacy and Safety of Use of Drug Product Reamberin® for Pathogenetic Therapy of Viral Enteric Infection in Children Aged 1-6 Years Old
StatusRecruiting
PhaseNot specified
Primary completion (estimated)
At risk: Primary completion moved at least 11 months later.
See at-risk trials from POLYSAN Scientific & Technological Pharmaceutical Company
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗
Notable Primary completion pushed from Jun 2026 to Jun 2027 Show 4 more changesShow less
- Eligibility criteria expanded, about 13 words
- Study completion pushed from Dec 2026 to Dec 2027
- Secondary endpoints: details revised at 1 of 10 entries
- Site details revised at 2 of 8 sites
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Proportion of patients in groups who continued to receive infusion therapy 24 hours and 48 hours after the start of the treatment
Timeframe: 24 hours, 48 hours
Average duration of infusion therapy in groups, expressed in days
Timeframe: Day 10
Average durations of symptoms of damage of the gastrointestinal tract in groups
Timeframe: Day 10
Average duration of symptoms of intoxication in groups
Timeframe: Day 10
Share of patients in groups with moderate form and severe form 48 hours after the start of the treatment
Timeframe: 48 hours
Average duration of stay of patients in an inpatient healthcare facility
Timeframe: Day 10
Secondary (10)
Average volume of infusion therapy relative to body weight
Dynamics of intoxication symptoms after 24 hours and 48 hours
Proportion of patients with electrolyte disturbances after 24 hours
Proportion of patients with base deficit (BE) less than 2 mmol/L after 24 hours
Dynamics of fever severity after 24 hours and 48 hours
Show 5 moreShow less
Average duration of fever
Average duration of stay in the ICU
Dynamics of symptoms of damage of the GI tract 24 hours and 48 hours
Dynamics of severity of dehydratation according to the CDS clinical scale 24 hours and 48 hours after the start of infusion therapy
Dynamics of changes of parameters of complete blood count and leukocytic index of intoxication 24 hours and 48 hours
Arms and interventions
Treatment group
Reamberin® in daily dose 10 mL/kg + normal saline (NaCl)/5 % or 10 % solution of glucose
Control group
Normal saline NaCl/Ringer's solution/5 % or 10 % solution of glucose
Drugs: Reamberin® solution for infusion, 1.5 %
Sites
8 sites in 2 countries
Russia 7, Uzbekistan 1